GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Total Inventories

Immunogen (Immunogen) Total Inventories : $5.5 Mil (As of Sep. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Immunogen Total Inventories?

Immunogen's total inventories for the quarter that ended in Sep. 2023 was $5.5 Mil. Immunogen's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Sep. 2023 was $4.4 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Immunogen's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $1.68.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Immunogen's Days Inventory for the three months ended in Sep. 2023 was 184.79.

Inventory Turnover measures how fast the company turns over its inventory within a year. Immunogen's Inventory Turnover for the quarter that ended in Sep. 2023 was 0.49.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Immunogen's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 0.04.


Immunogen Total Inventories Historical Data

The historical data trend for Immunogen's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Total Inventories Chart

Immunogen Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunogen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.61 3.23 5.50

Immunogen Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Immunogen  (NAS:IMGN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Immunogen's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is

Net-Net Working Capital Per Share (Q: Sep. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(605.535+0.75 * 130.694+0.5 * 5.495-260.505
-0-0)/265.842
=1.68

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Immunogen's Days Inventory for the three months ended in Sep. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2023 )/Cost of Goods Sold (Q: Sep. 2023 )*Days in Period
=4.364/2.155*365 / 4
=184.79

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Immunogen's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2023 ) / Average Total Inventories (Q: Sep. 2023 )
=2.155 / 4.364
=0.49

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Immunogen's Inventory to Revenue for the quarter that ended in Sep. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=4.364 / 113.425
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Immunogen Total Inventories Related Terms

Thank you for viewing the detailed overview of Immunogen's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunogen (Immunogen) Business Description

Traded in Other Exchanges
Address
830 Winter Street, Waltham, MA, USA, 02451
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.
Executives
Theresa Wingrove officer: VP of Regulatory Affairs IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini officer: V.P.-Fin., Prin. Acctg. Off. 830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen officer: Chief Business Officer 11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White officer: SVP, CFO and PFO C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy director, officer: Chief Executive Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos officer: SVP & CHIEF COMMERCIAL OFFICER C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles officer: EVP R&D & MEDICAL AFFAIRS C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char officer: SVP & CHIEF LEGAL OFFICER C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith officer: SVP & Chief Commercial Officer C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain director C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster officer: V.P.-Fin., Prin. Acctg. Off. C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller officer: SVP and CFO 45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows officer: Vice-President,General Counsel C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451